{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T21:01:06Z","timestamp":1778274066922,"version":"3.51.4"},"reference-count":29,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2006,8,1]],"date-time":"2006-08-01T00:00:00Z","timestamp":1154390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2006,8]]},"DOI":"10.1016\/j.pnpbp.2006.03.014","type":"journal-article","created":{"date-parts":[[2006,4,27]],"date-time":"2006-04-27T15:37:09Z","timestamp":1146152229000},"page":"1163-1166","source":"Crossref","is-referenced-by-count":49,"title":["Severe liver enzyme elevations after three years of olanzapine treatment: A case report and review of olanzapine associated hepatotoxicity"],"prefix":"10.1016","volume":"30","author":[{"given":"Tuba","family":"Ozcanli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayten","family":"Erdogan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuray","family":"Ozdemir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bar\u0131\u015f","family":"Onen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mine","family":"Ozmen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerem","family":"Doksat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdullah","family":"Sonsuz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2006.03.014_bib1","series-title":"Diagnostic and statistical manual of mental disorders (DSM-IV)","first-page":"273","author":"American Psychiatric Association","year":"1994"},{"key":"10.1016\/j.pnpbp.2006.03.014_bib2","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/10401230490453293","article-title":"Atypical antipsychotic induced weight gain: pathophysiology and management","volume":"16","author":"Ananth","year":"2004","journal-title":"Ann Clin Psychiatry"},{"issue":"6","key":"10.1016\/j.pnpbp.2006.03.014_bib3","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.pnpbp.2005.04.037","article-title":"Safety and effectiveness of olanzapine in monotherapy: a multivariate analysis of a naturalistic study","volume":"29","author":"Ciudad","year":"2005","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2006.03.014_bib4","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1176\/appi.ajp.158.5.765","article-title":"A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder","volume":"158","author":"Conley","year":"2001","journal-title":"Am J Psychiatry"},{"issue":"Suppl 8","key":"10.1016\/j.pnpbp.2006.03.014_bib29","first-page":"26","article-title":"Adverse events related to olanzapine","volume":"61","author":"Conley","year":"2000","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"10.1016\/j.pnpbp.2006.03.014_bib5","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.bpg.2004.06.021","article-title":"Non-alcoholic fatty liver disease\/non-alcoholic steatohepatitis (NAFLD\/NASH): diagnosis and clinical course","volume":"18","author":"Cortez-Pinto","year":"2004","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"10","key":"10.1016\/j.pnpbp.2006.03.014_bib6","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1345\/aph.19390","article-title":"Olanzapine-induced acute pancreatitis","volume":"34","author":"Doucette","year":"2000","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.pnpbp.2006.03.014_bib7","first-page":"542","article-title":"Hepatic tolerance of atypical antipsychotic drugs","volume":"28","author":"Dumotier","year":"2002","journal-title":"Encephale"},{"key":"10.1016\/j.pnpbp.2006.03.014_bib8","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2190\/44WA-WXF7-3UHA-FDV1","article-title":"Management of marked liver enzyme increase during clozapine treatment: a case report and review of the literature","volume":"34","author":"Erdogan","year":"2004","journal-title":"Int J Psychiatry Med"},{"key":"10.1016\/j.pnpbp.2006.03.014_bib9","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/00004714-200104000-00014","article-title":"Relevance of liver enzyme elevations with four different neuroleptics: a retrospective review of 7263 treatment courses","volume":"21","author":"Gaertner","year":"2001","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2006.03.014_bib10","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.eurpsy.2003.06.002","article-title":"Olanzapine versus risperidone: weight gain and elevation of serum triglyceride levels","volume":"18","author":"Garyfallos","year":"2003","journal-title":"Eur Psychiatry"},{"key":"10.1016\/j.pnpbp.2006.03.014_bib11","doi-asserted-by":"crossref","first-page":"335","DOI":"10.4088\/JCP.v61n0503","article-title":"The safety of olanzapine compared with other antipsychotic drugs: results of an observational prospective study in patients with schizophrenia (EFESO Study). Pharmacoepidemiologic study of olanzapine in schizophrenia","volume":"61","author":"Gomez","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2006.03.014_bib12","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1097\/00004583-200310000-00014","article-title":"Retrospective study of hepatic enzyme elevations in children treated with olanzapine, divalproex and their combination","volume":"42","author":"Gonzalez-Heydrich","year":"2003","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.pnpbp.2006.03.014_bib13","doi-asserted-by":"crossref","first-page":"851","DOI":"10.4088\/JCP.v64n0718f","article-title":"Nonalcoholic steatohepatitis: a possible side effect of atypical antipsychotics","volume":"64","author":"Haberfellner","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2006.03.014_bib14","first-page":"314","article-title":"Hepatotoxicity of clozapine","volume":"17","author":"Hummer","year":"1997","journal-title":"J Clin Pharmacol"},{"issue":"138","key":"10.1016\/j.pnpbp.2006.03.014_bib15","doi-asserted-by":"crossref","first-page":"357","DOI":"10.7326\/0003-4819-138-4-200302180-00024","article-title":"Acute hepatocellular\u2013cholestatic liver injury after olanzapine therapy","volume":"18","author":"Jadallah","year":"2003","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.pnpbp.2006.03.014_bib16","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1592\/phco.23.10.1123.32759","article-title":"Pancreatitis associated with atypical antipsychotics: from the Food and Drug Administration's MedWatch surveillance system and published reports","volume":"23","author":"Koller","year":"2003","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.pnpbp.2006.03.014_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00004583-199705000-00022","article-title":"Case study: risperidone-induced hepatotoxicity in pediatric patients","volume":"36","author":"Kumra","year":"1997","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.pnpbp.2006.03.014_bib18","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/S0025-7125(05)70287-X","article-title":"Drug-induced liver disease","volume":"84","author":"Lewis","year":"2000","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.pnpbp.2006.03.014_bib19","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S0278-5846(02)00263-4","article-title":"Liver function tests during treatment with antipsychotic drugs: a case series of 23 patients","volume":"26","author":"Mouradian-Stamatiadis","year":"2002","journal-title":"Prog Neuro-psychopharmacol Biol Psychiatry"},{"issue":"Suppl. 1","key":"10.1016\/j.pnpbp.2006.03.014_bib20","first-page":"1","article-title":"Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review","volume":"19","author":"Newcomer","year":"2005","journal-title":"CNS Drugs"},{"issue":"3","key":"10.1016\/j.pnpbp.2006.03.014_bib21","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/00004850-200505000-00009","article-title":"Naturalistic observation on the hepatic enzyme changes in patients treated with either risperidone or olanzapine alone","volume":"20","author":"Pae","year":"2005","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2006.03.014_bib22","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/00000441-200102000-00008","article-title":"A case report of olanzapine-induced hypersensitivity syndrome","volume":"321","author":"Raz","year":"2001","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.pnpbp.2006.03.014_bib23","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/15622970410029915","article-title":"Atypical antipsychotics and diabetes mellitus","volume":"5","author":"Schwenkreis","year":"2004","journal-title":"World J Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2006.03.014_bib24","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1002\/hep.510290535","article-title":"Hepatotoxicity of psychotropic drugs","volume":"29","author":"Selim","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.pnpbp.2006.03.014_bib25","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1089\/cap.1999.9.93","article-title":"Risperidone-induced hepatotoxicity in children and adolescents? A chart review study","volume":"9","author":"Szigethy","year":"1999","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2006.03.014_bib26","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/13651500410005577","article-title":"Hepatotoxicity, leucopenia and neutropenia associated with olanzapine therapy","volume":"8","author":"Tchernichovsky","year":"2004","journal-title":"Int J Psychiatry Clin Pract"},{"key":"10.1016\/j.pnpbp.2006.03.014_bib27","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1176\/ajp.154.4.457","article-title":"Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial","volume":"154","author":"Tollefson","year":"1997","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2006.03.014_bib28","unstructured":"Waage C., Carlsson H., Nielsen EW. (2004). Olanzapine-induced pancreatitis: a case report. JOP; 10;5(5): 388\u2013391."}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027858460600090X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027858460600090X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,16]],"date-time":"2019-01-16T23:50:28Z","timestamp":1547682628000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S027858460600090X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["S027858460600090X"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2006.03.014","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2006,8]]}}}